VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 24 2025
0mins
Source: Newsfilter
VivoSim Labs Emerges from Stealth Mode: VivoSim Labs has launched its innovative drug discovery methodologies that utilize non-animal testing models, aligning with the FDA's initiative to phase out animal testing. The company aims to disrupt the $10B animal testing market by providing more predictive and ethically sound alternatives.
Transformative Impact on Drug Development: VivoSim's NAMkind models are designed to significantly reduce clinical trial failures and development costs by improving predictions of liver and intestinal toxicity, ultimately leading to safer treatments for patients while addressing challenges faced in current drug evaluation processes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
